These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28649871)

  • 1. The potential role of nintedanib in treating colorectal cancer.
    Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
    Capdevila J; Carrato A; Tabernero J; Grande E
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib for the treatment of non-small-cell lung cancer.
    Rashdan S; Hanna N
    Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor.
    Reck M
    Expert Rev Anticancer Ther; 2015 May; 15(5):579-94. PubMed ID: 25831142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
    Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib in ovarian cancer.
    Khalique S; Banerjee S
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1073-1081. PubMed ID: 28721753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
    Fakih M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
    Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
    Paluri R; Madan A; Li P; Jones B; Saleh M; Jerome M; Miley D; Keef J; Robert F
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):551-559. PubMed ID: 30603797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
    Giampieri R; Caporale M; Pietrantonio F; De Braud F; Negri FV; Giuliani F; Pusceddu V; Demurtas L; Restivo A; Fontanella C; Aprile G; Cascinu S; Scartozzi M
    Crit Rev Oncol Hematol; 2016 Apr; 100():99-106. PubMed ID: 26907512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
    Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
    Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
    Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
    Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
    Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Hinz S; Brekken RA; Schwarz MA; Schwarz RE
    Cancer Lett; 2015 Mar; 358(1):59-66. PubMed ID: 25527450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.